Immunocore Holdings Plc Stock Price, News & Analysis

Acacia Research Corporation (ACTG) reported a Q2 2022 revenue of $16.7 million, down from $17.4 million in Q2 2021. The company recorded $11.5 million in realized gains, including $5.2 million from its Life Science Portfolio. Acacia repurchased 6.1 million shares at an average price of $4.64 as part of a $40 million buyback program. Additionally, the company repaid $50 million in debt. However, there was a substantial GAAP net loss of $61.5 million compared to a net income of $19.7 million last year.

Immunocore reported Q2 2022 revenues of £27.7 million ($33.7 million) from KIMMTRAK, with U.S. sales at £18.1 million and European sales at £5.9 million. The company transitioned over 50 patients to commercial supply in Germany and finalized a randomized Phase 2/3 trial protocol for tebentafusp in advanced melanoma. Cash equivalents stood at £208 million ($253 million) as of June 30, 2022, following a £117 million PIPE financing in July. KIMMTRAK is now approved in over 30 countries, marking significant growth for the company.

Immunocore Holdings plc (Nasdaq: IMCR) will announce its Second Quarter 2022 Earnings on August 10, 2022, prior to market opening. Following this, the company will host a live teleconference and webcast at 8:00 a.m. EDT. The company focuses on developing T cell receptor bispecific immunotherapies for various diseases, including cancer. Its leading oncology drug, KIMMTRAK, is FDA-approved for treating unresectable or metastatic uveal melanoma, showing significant survival benefits in clinical trials.

Immunocore has announced an upcoming oral presentation of initial data from its Phase 1 study of IMC-F106C, a bispecific T cell receptor candidate targeting PRAME, at the ESMO Congress 2022. The presentation is scheduled for September 9, 2022, at 4:50 PM CEST, along with four additional poster presentations on September 10. This study represents a significant milestone in Immunocore's development of ImmTAC therapies for solid tumors, showcasing their innovative approach to cancer treatment.

Immunocore announced a $140 million private placement financing, agreeing to sell 3,733,333 shares, including 2,000,000 American Depository Shares at $37.50 each. The financing, with participation from existing investors like RTW Investments and General Atlantic, aims to fund clinical developments for oncology and infectious diseases.

Proceeds will support the advancement of tebentafusp in advanced cutaneous melanoma among other candidate programs and working capital through 2025.

Immunocore has announced the dosing of the first patient in the Phase 1 clinical trial of IMC-M113V, a T cell receptor bispecific therapy targeting HIV. This therapy aims to eliminate CD4+ cells infected with HIV, potentially leading to viral suppression without the need for lifelong antiretroviral therapy. IMC-M113V is the second candidate developed using Immunocore’s ImmTAV platform. The trial will assess its safety, antiviral activity, and pharmacokinetics in HLA-A*02:01 positive patients. The company collaborates with the Bill and Melinda Gates Foundation to ensure global access to the treatment.

Argenta has appointed Paul Fry as its new Chief Financial Officer, effective immediately, following the transition from former CFO Chris O’Donnell. This strategic move relocates the CFO role from New Zealand to London for better collaboration. Fry brings extensive financial expertise from various industries and has a track record of enhancing company valuations, including his previous role at Immunocore Limited. The CEO, Will Downie, expressed confidence in Fry's potential to drive long-term growth.

Argenta specializes in animal health R&D and manufacturing, operating globally.

Immunocore presented initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress. The study evaluated the safety and antiviral activity of IMC-I109V, a T cell receptor bispecific targeting HBsAg. Initial results showed that a single low dose led to transient declines in HBsAg levels and ALT elevations, aligning with the drug's mechanism of action. No adverse events were reported, indicating a favorable safety profile. The trial aims for a functional cure for HBV, with a focus on further patient enrollment and dose escalation.

Immunocore has appointed Siddharth Kaul to its Board of Directors, effective June 8, 2022. Kaul, a seasoned finance expert with extensive life sciences experience, previously held significant roles at Novartis and Procter & Gamble. He will contribute as a Class II director and participate in the Audit and Remuneration committees. This appointment aligns with Immunocore's focus on the commercial rollout of its lead product, KIMMTRAK, for treating metastatic uveal melanoma and enhancing its oncology and infectious disease pipeline.